BioSpace News Archive

Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, announced it has appointed Meeta Gulyani to serve on its Board of Directors.

AnaptysBio, Inc., a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, announced the appointment of Mr. Daniel Faga to the company’s Board of Directors.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on January 5, 2022 to all shareholders of record as of December 15, 2021.

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to TherapeuticsTM” is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a fireside chat at the 2nd Annual H.C. Wainwright Psychedelics Conference.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company reducing the cost and complexity of dialysis, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for a new sterilization method of the cartridge utilized in its Tablo® Hemodialysis System, enabling full production in North America.

Pasithea Therapeutics Corp., a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, announced the closing of its previously announced private placement of common stock and warrants priced at a premium to the market under Nasdaq rules.

LabGenius, the machine learning (ML)-driven protein engineering company, today announced the appointment of Gino Van Heeke Ph.D. as Chief Scientific Officer (CSO).

Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue” or the “Company”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the FDA has informed the Company that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee is tentatively scheduled for February 15, 2022.

Hyperfine, Inc., creator of the first FDA-cleared portable magnetic resonance imaging (MRI) device, Swoop®, today announced the FDA 510(k) clearance and launch of its new advanced image reconstruction technology using deep learning (DL).

Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company”), reported today that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are predicted to interfere with any of the Company’s suite of COVID-19 PCR diagnostic assays.